book cover

Palliative Care Perspectives : Chapter 5: Non-Pain Symptom Management : References for Chapter 5

1. Hornby, P. J. Central neurocircuitry associated with emesis. Am J Med 2001; 111(suppl 8A): 106S-12S.

2. Mannix, K. Palliation of nausea and vomiting. In: D. Doyle, G. Hanks, et al., eds. The Oxford Textbook of Palliative Medicine. 1998, Oxford University Press: New York, pp. 490-8.

3. Rousseau, P. Non-pain symptom management in terminal care. Clin Geriatr Med 1996; 12: 313-6.

4. Hesketh, P. J. et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ- 11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999; 17(1): 338-43.

5. Hesketh, P. J. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 2001; 9(5): 350-4.

6. Twycross, R. Pain Relief in Advanced Cancer. 1994, Churchill Livingstone: London.

7. Malik, I. A. et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 1995; 18(2): 170-5.

8. Priestman, T. J. et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol) 1990; 2(2): 71-5.

9. Priestman, T. J., J. T. Roberts, et al. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol 1993; 5(6): 358-63.

10. Roberts, J.T. and T.J. Priestman. A review of ondansetron in the management of radiotherapy-induced emesis. Oncology 1993; 50(3): 173-9.

11. Diemunsch, P. and L. Grelot. Potential of substance P antagonists as antiemetics. Drugs 2000; 60(3): 533-46.

12. Peroutka, S. J. and S. H. Snyder. Antiemetics: Neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982; 1(8273): 658-9.

13. Terndrup, T. E. et al. Comparison of intramuscular meperidine and promethazine with and without chlorpromazine: A randomized, prospective, double-blind trial. Ann Emerg Med 1993; 22(2): 206-11.

14. Ernst, A. A. et al. Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: A randomized, double-blind clinical trial. Ann Emerg Med 2000; 36(2): 89-94.

15. Bruera, E. and et al. Chronic nausea in advanced cancer patients: A retrospective assessment of metoclopramide-based anti-emetic regimen. J Pain Symptom Manage 1996; 11: 147-53.

16. Loewen, P. S., C. A. Marra, et al. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Can J Anaesth 2000; 47(10): 1008-18.

17. Hoskin, P. Radiotherapy in symptom management. In: D. Doyle, G. Hanks, et al., eds. The Oxford Textbook of Palliative Medicine. 1998, Oxford University Press: New York, pp. 267-82.

18. Kast, R. E. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001; 9(6): 469-70.

19. Tramer, M. R. et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ 2001; 323(7303): 16-21.

20. Hallenbeck, J. and D. E. Weissman. Fast Fact and Concept #5: Treatment of nausea and vomiting. End of Life Education Project. http://www.eperc.mcw.edu/, 2000.

21. Enck, R. The Medical Care of Terminally Ill Patients. 1994, Johns Hopkins University Press: Baltimore, pp. 28-32.

22. Mancini, I. and E. Bruera. Constipation in advanced cancer patients. Support Care Cancer 1998; 6(4): 356-64.

23. Bruera, E. et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: A retrospective review. J Pain Symptom Manage 1994; 9(8): 515-9.

24. Hallenbeck, J. and D. E. Weissman. Fast Fact and Concept #15; Constipation. End of Life Education Project. http://www.eperc.mcw.edu/, 2000.

25. Fallon, M. and B. O'Neill. ABC of palliative care. Constipation and diarrhoea. BMJ 1997; 315(7118): 1293-6.

26. Ahmedzai, S. and D. Brooks. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. The TTS-Fetanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13: 254-61.

27. Radbruch, L. et al. Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14: 111-9.

28. Hunt, R. et al. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manag 1999; 18: 111-9.

29. Hurdon, V., R. Viola, et al. How useful is docusate in patients at risk for constipation? A systematic review of the evidence in the chronically ill. J Pain Symptom Manage 2000; 19(2): 130-6.

30. Ripamonti, C. et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001; 9(4): 223-33.

31. Beattie, G., F. Leonard, et al. Bowel obstruction in ovarian carcinoma: A retrospective study and review of the literature. Palliat Med 1981; 3: 275-80.

32. Baines, M., D. Oliver, et al. Medical management of intestinal obstruction in patients with advanced malignant disease: A clinical and pathologic study. Lancet 1985; ii: 990-3.

33. Welch, J. Bowel Obstruction. 1990, WB Saunders: Philadelphia.

34. Hutchison, S., G. Beattie, et al. Increased serotonin excretion in patients with ovarian carcinoma of the ovary. Palliat Med 1995; 9: 67-8.

35. Cubeddu, L. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 1996; 53(suppl 1): 18-25.

36. Isbister, W., P. Elder, et al. Non-operative management of malignant intestinal obstruction. Journal of the Royal College of Physicians of Edinburgh 1990; 35: 369-72.

37. Ventafridda, V. et al. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 1990; 76: 389-93.

38. Aranha, G., F. Folk, et al. Surgical palliation of small bowel obstruction due to metastatic carcinoma. Am Surg 1981; 13: 44-9.

39. Krebs, H. and D. Goplerud. The role of intestinal intubation in obstruction of the small intestine due to carcinoma of the ovary. Surgery, Gynecology, and Obstetrics 1984; 158: 467-71.

40. Bizar, L. et al. Small bowel obstruction. Surgery 1981; 89: 407-13.

41. Osteen, R. et al. Malignant intestinal obstruction. Surgery 1980; 67: 611-5.

42. De Conno, F. et al. Continuous subcutaneous infusion of hyscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 1991; 6: 484-6.

43. Hardy, J. et al. Pitfalls in placebo-controlled trials in palliative care: Dexamethasone for the palliation of malignant bowel obstruction. Palliat Med 1998; 9: 67-8.

44. Tuna, J., D. Buchler, et al. The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol 1981; 12: 186-92.

45. Soetikno, R., D. Lichtenstein, et al. Palliation of malginant gastric outlet obstruction using an endoscopically placed wallstent. Gastrointest Endosc 1998; 12: 267-70.

46. Friedland, S., J. Hallenbeck, et al. Stenting the sigmoid colon in a terminally ill patient with prostate cancer. Journal of Palliative Medicine 2001; 4(2): 153-6.

47. Mangli, G., M. Franchi, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 1996; 61: 345-8.

48. Khoo, D., E. Hall, et al. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994; 30: 28-30.

49. Mercadante, S. et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000; 8(3): 188-91.

50. Ripamonti, C. et al. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial. J Pain Symptom Manage 2000; 19(1): 23-289.

51. Fainsinger, R. et al. Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manage 1994; 9: 12-8.

52. Feinle, C. and N. Read. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol 1996; 271: 6591-7.

53. Ventafridda, V. et al. Mouth care. In: D. Doyle, G. Hanks, et al., eds. The Oxford Textbook of Palliative Medicine. 1998, Oxford University Press: New York, pp. 691-8.

54. Ng, K. and C. F. von Gunten. Symptoms and attitudes of 100 consecutive patients admitted to an acute hospice/palliative care unit. J Pain Symptom Manage 1998; 16(5): 307-16.

55. McCann, R. M., W. J. Hall, et al. Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272(16): 1263-6.

56. Stern, L. Preliminary study of glycopyrrolate in the management of drooling. J Paediatr Child Health 1997; 33: 52-4.

57. Olsen, A. K. and P. Sjogren. Oral glycopyrrolate alleviates drooling in a patient with tongue cancer. J Pain Symptom Manage 1999; 18: 300-2.

58. Ripamonti, C. and E. Bruera. Dyspnea: Pathophysiology and assessment. J Pain Symptom Manage 1997; 13(4): 220-32.

59. Reuben, D. B. and V. Mor. Dyspnea in terminally ill cancer patients. Chest 1986; 89(2): 234-6.

60. Bruera, E. et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 2000; 19(5): 357-62.

61. Skilbeck, J. Palliative care in chronic obstructive airways disease: A needs assessment. Palliat Med 1998; 12: 245-54.

62. Watanabe, S. The role of oxygen in cancer-related dyspnea. In: R. Portenoy and E. Bruera, eds. Topics in Palliative Care. 2000, Oxford University Press: New York, pp. 255-60.

63. Bruera, E. et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342(8862): 13-4.

64. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: A consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999; 159(1): 321-40.

65. Cristiano, L. M. and R. M. Schwartzstein. Effect of chest wall vibration on dyspnea during hypercapnia and exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155(5): 1552-9.

66. Edo, H. et al. Effects of chest wall vibration on breathlessness during hypercapnic ventilatory response. J Appl Physiol 1998; 84(5): 1487-91.

67. Nakayama, H. et al. In-phase chest wall vibration decreases dyspnea during arm elevation in chronic obstructive pulmonary disease patients. Intern Med 1998; 37(10): 831-5.

68. Bruera, E. et al. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage 1990; 5(6): 341-4.

69. Mazzocato, C., T. Buclin, et al. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double-blind controlled trial. Ann Oncol 1999; 10(12): 1511-4.

70. Zeppetella, G. Nebulized morphine in the palliation of dyspnoea. Palliat Med 1997; 11: 267-73.

71. Chandler, S. Nebulized opioids to treat dyspnea. American Journal of Hospice & Palliative Care 1999; 16(1): 418-22.

72. Stark, R. D. et al. Effects of small-particle aerosols of local anaesthetic on dyspnoea in patients with respiratory disease. Clin Sci (Colch) 1985; 69(1): 29-36.

73. Libby, D., W. Briscoe, et al. Relief of hypoxia-related bronchoconstriction by breathing 30 percent oxygen. American Review of Respiratory Disease 1981; 123: 171-5.

74. Liss, H. and B. Grant. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. American Review of Respiratory Disease 1988; 137: 1285-8.

75. Brennan, M. F. Uncomplicated starvation versus cancer cachexia. Cancer Res 1977; 37(7 pt 2): 2359-64.

76. Dulloo, A. G., J. Jacquet, et al. Poststarvation hyperphagia and body fat overshooting in humans: A role for feedback signals from lean and fat tissues. Am J Clin Nutr 1997; 65(3): 717-23.

77. Alexander, H. Prevalence and pathophysiology of cancer cachexia. In: R. K. Portenoy and E. Bruera, eds. Topics in Palliative Care. 1998, Oxford University Press: New York, pp. 91-129.

78. Inui, A. Cancer anorexia-cachexia syndrome: Are neuropeptides the key? Cancer Res 1999; 59(18): 4493-501.

79. Dunlop, R. J. and C. W. Campbell. Cytokines and advanced cancer. J Pain Symptom Manage 2000; 20(3): 214-32.

80. Freeman, L. M. and R. Roubenoff. The nutrition implications of cardiac cachexia. Nutr Rev 1994; 52(10): 340-7.

81. Nemechek, P. M., B. Polsky, et al. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 2000; 75(4): 386-94.

82. Neuenschwander, H. and E. Bruera. Pathophysiology of cancer asthenia. In: R. K. Portenoy and E. Bruera, eds. Topics in Palliative Care. 1998, Oxford University Press: New York, pp. 171-81.

83. Cleary, J. F. The reversible causes of asthenia in cancer patients. In: R. K. Portenoy and E. Bruera, eds. Topics in Palliative Care. 1998, Oxford University Press: New York, pp. 183-202.

84. Vigano, A., S. Watanabe, et al. Anorexia and cachexia in advanced cancer patients. Cancer Surv 1994; 21: 99-115.

85. De Conno, F. et al. Megestrol acetate for anorexia in patients with far-advanced cancer: A double-blind controlled clinical trial. Eur J Cancer 1998; 34(11): 1705-9.

86. Yanagawa, H. et al. Palliative steroid therapy and serum interleukin-6 levels in a patient with lung cancer. J Pain Symptom Manage 1996; 12(3): 195-8.

87. Beal, J., R. Olson, et al. Dronabinol as treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89.

88. Gleeson, C. Blood transfusion and its benefits in palliative care. Palliat Med 1995; 9(4): 307-13.

<<< Previous [ Go Up ]



book cover

Palliative Care Perspectives

James L. Hallenbeck, M.D.

Order hardback from Amazon.com
Order paperback from Amazon.com

Copyright 2003 by Oxford University Press, Inc.

The online version of this book is used with permission of the publisher and author on web sites affiliated with the Inter-Institutional Collaborating Network on End-of-life Care (IICN), sponsored by Growth House, Inc.